Profound on-treatment viral suppression with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus lamivudine combination therapy limits the development of YMDD mutations, but does not improve sustained response rates over peginterferon alfa-2a (40KD) alone
55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 29 October - 02 November 2004, vol.40, (Summary Text)
- Publication Type: Conference Paper / Summary Text
- Volume: 40
- City: Massachusetts
- Country: United States Of America
- Ankara University Affiliated: No